Zhejiang Hisun, Celsion Sign Pact To Develop ThermoDox In China
This article was originally published in PharmAsia News
Executive Summary
China's Zhejiang Hisun Pharmaceutical and Celsion have signed a co-development agreement for the U.S. company's ThermoDox (doxorubicin) for treating liver cancer in China, Hong Kong and Macau.